Influence of delays to nonemergent colon cancer surgery on operative mortality, disease-specific survival and overall survival.
BACKGROUND: There has been minimal research on the influence of delays for cancer treatments on patient outcomes. We measured the influence of delays to nonemergent colon cancer surgery on operative mortality, disease-specific survival and overall survival. METHODS: We used the linked Surveillance, Epidemiology and End Results (SEER)-Medicare databases (1993-1996) to identify patients who underwent nonemergent colon cancer surgery. We assessed 2 time intervals: surgeon consult to hospital admission for surgery and first diagnostic test for colon cancer to hospital admission. Follow-up data were available to the end of 2003. We selected the time intervals to create patient groups with clinical relevance and they did not extend past 120 days. RESULTS: We identified 7989 patients who underwent nonemergent colon cancer surgery. Median delays from surgeon consult to admission and from first diagnostic test to admission were 7 and 17 days, respectively. The odds of operative mortality were similar if the consult-to-admission interval was 22 days or more versus 1-7 days (odds ratio [OR] 1.0, 95% confidence interval [CI] 0.6-1.8, p = 0.91) or if the test-to-admission interval was 43 days or more versus 1-14 days (OR 0.8, 95% CI 0.4-1.5, p = 0.51), respectively. For these same respective interval comparisons, disease-specific survival was not influenced by the consult-to-admission wait (hazard ratio [HR] 1.0, 95% CI 0.9-1.2, p = 0.91) or the test-to-admission wait (HR 1.0, 95% CI 0.8-1.1, p = 0.63). The risk of death was slightly greater if the consult-to-admission interval was 22 or more days versus 1-7 days (HR 1.1, 95% CI 1.0-1.2, p = 0.013) and if the test-to-admission interval was 43 days or more versus 1-14 days (HR 1.2, 95% CI 1.1-1.3, p = 0.003). CONCLUSION: It is unlikely that delays to nonemergent colon cancer surgery longer than 3 weeks from initial surgical consult or longer than 6 weeks from first diagnostic test negatively impact operative mortality, disease-specific survival or overall survival.
Simunovic
Marko
M
Departments of Surgery.
Rempel
Eddy
E
Thériault
Marc-Erick
ME
Baxter
Nancy N
NN
Virnig
Beth A
BA
Meropol
Neal J
NJ
Levine
Mark N
MN
Cancer Pract. 1999 May-Jun;7(3):130-5
10352075
Br J Cancer. 1999 Feb;79(5-6):858-64
10070881
Eur J Surg Oncol. 1999 Apr;25(2):173-8
10218461
Med Care. 1993 Aug;31(8):732-48
8336512
J Clin Epidemiol. 1992 Jun;45(6):613-9
1607900
Med Care. 2002 Aug;40(8 Suppl):IV-3-18
12187163
Med Care. 1996 Sep;34(9):970-84
8792784
Oncol Nurs Forum. 1994 Nov-Dec;21(10):1723-7
7854934
Can J Surg. 2002 Apr;45(2):109-15
11939652
CMAJ. 2001 Apr 17;164(8):1133-8
11338798
Int J Cancer. 2002 Jan 1;97(1):72-81
11774246
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Anticancer Res. 1996 Mar-Apr;16(2):995-9
8687166
Med Care. 2002 Aug;40(8 Suppl):IV-55-61
12187169
J Clin Oncol. 2003 Feb 1;21(3):555-63
12560449
Am J Public Health. 1996 Apr;86(4):582-6
8604797
Can J Surg. 2005 Apr;48(2):137-42
15887794
Med Care. 2002 Aug;40(8 Suppl):IV-49-54
12187168
Eur J Cardiothorac Surg. 1997 Dec;12(6):880-4
9489874
J Natl Cancer Inst. 2001 Jun 6;93(11):850-7
11390534